Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.16M | $41.0M | $3.12M | $290M | $719K | $915M | $1.20M | $371M | $37.3M | $3.51M |
| Revenue growth | — | 693.9% | -92.4% | 9169.8% | -99.8% | 127154.9% | -99.9% | 30885.5% | -89.9% | -90.6% |
| Operating income | -$68.1M | -$64.6M | -$159M | $46.7M | -$354M | $374M | -$673M | -$223M | -$467M | -$665M |
| Operating margin | -1319.3% | -157.7% | -5087.8% | 16.1% | -49295.5% | 40.8% | -56190.4% | -60.0% | -1250.4% | -18933.6% |
| Net income | -$23.2M | -$68.4M | -$165M | $66.9M | -$349M | $378M | -$650M | -$154M | -$366M | -$582M |
| Net margin | -448.8% | -166.7% | -5281.1% | 23.1% | -48520.9% | 41.3% | -54271.7% | -41.4% | -981.5% | -16569.8% |
| EPS (diluted) | -$1.89 | -$1.71 | -$3.44 | $1.17 | -$5.29 | $4.70 | -$8.36 | -$1.94 | -$4.34 | -$6.47 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$52.9M | -$70.1M | -$96.2M | $56.7M | -$238M | $539M | -$496M | -$260M | -$143M | -$345M |
| Capital expenditures | $3.02M | $7.81M | $2.77M | $6.68M | $18.4M | $81.7M | $37.2M | $9.47M | $1.90M | $914K |
| Free cash flow | -$55.9M | -$77.9M | -$99.0M | $50.0M | -$257M | $457M | -$533M | -$270M | -$145M | -$346M |
| Share buybacks | — | — | $57.0K | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $316M | $240M | $457M | $944M | $1.17B | $923M | $212M | $389M | $298M | $348M |
| Total assets | $345M | $271M | $489M | $1.07B | $1.83B | $2.75B | $2.24B | $2.23B | $2.24B | $2.27B |
| Total liabilities | $112M | $83.5M | $96.8M | $127M | $164M | $352M | $368M | $347M | $310M | $343M |
| Shareholders' equity | $233M | $188M | $392M | $939M | $1.66B | $2.40B | $1.88B | $1.88B | $1.93B | $1.92B |
| Retained earnings | -$57.1M | -$125M | -$292M | -$225M | -$574M | -$196M | -$846M | -$1000M | -$1.37B | -$1.95B |
| Shares (wtd avg diluted) | 39.7M | 40.1M | 48.0M | 56.9M | 65.9M | 80.4M | 77.7M | 79.2M | 84.4M | 89.9M |
Every figure is extracted from CRISPR Therapeutics AG’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.